Interestingly, SGLT2 inhibitors are precisely able to produce energy conservation effects similar to “fasting” with increased levels of circulating ketones in serum, as seen in T2DM (Polidori et al., 2018). Here, SLC5A2 is linked to type 2 diabetes mellitus.